We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Download Mobile App




Global Point-of-Care (POC) Testing Market to Reach Nearly USD 80 Billion by 2028 due to Increasing Dominance of Infectious Diseases

By LabMedica International staff writers
Posted on 15 Oct 2021
Print article
Illustration
Illustration

The global Point-Of-Care (POC) testing market is projected to grow at a CAGR of 12.3% from USD 31.17 billion in 2020 to USD 78.85 billion by 2028, driven mainly by the increasing dominance of infectious diseases, hematological diseases, cancer, and others.

These are the latest findings of Zion Market Research (New York, NY, USA), a global market research company.

POC testing devices are mainly used for diagnosis of disease for early detection and monitoring along with its effective treatment and management. During the last few decades, there has been a significant growth in the pervasiveness of chronic diseases which has led to an upsurge in patient inflow. POC tests are beneficial in providing instantaneous results to the patient. However, the introduction of new tests and devices in the market require manufacturers to meet strict government regulations. These stringent government regulations and poor reimbursement policies could hinder the growth of the global POC testing market. The decentralization of healthcare is one of the major trends being currently observed in patient care and is anticipated to offer new market growth opportunities.

The COVID-19 pandemic has accelerated the global demand for diagnostic kits for rapid detection of the diseases. As a result, several market players are focusing on increasing the supply of tests worldwide. Owing to an increase in chronic diseases and patients suffering from such diseases, there is growing healthcare awareness among people which is also fueling the growth of the POC testing market. Increasing government support, along with the rising number of clinics adopting POC tests for the rapid detection of infectious diseases in the near future are expected to continue driving the growth of the POC testing market during the forecast period. However, multi-layered regulations set by the FDA and laboratory regulations under CLIA could restrain the market growth.

Nevertheless, greater acceptance of new technologies among researchers and academia, technological advancements, large base of population suffering from chronic and acute diseases, and increasing number of end users such as hospitals and clinics, outpatient & ambulatory care facilities are likely to continue driving the growth of the global POC testing market.

Geographically, North America holds the largest share of the global POC testing market owing to its huge patient population, well developed economies and high healthcare expenditure. Additionally, North America is also home to the key market players, supportive governments, people with higher awareness of self-testing and home care products, and a population that has significant adoption of novel technologies. On the other hand, Asia Pacific is anticipated to be the fastest growing market for POC testing due to its huge population base.

Related Links:
Zion Market Research 

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
New
Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Microbiology

view channel
Image: Microscope image showing human colorectal cancer tumor with Fusobacterium nucleatum stained in a red-purple color (Photo courtesy of Fred Hutch Cancer Center)

Mouth Bacteria Test Could Predict Colon Cancer Progression

Colon cancer, a relatively common but challenging disease to diagnose, requires confirmation through a colonoscopy or surgery. Recently, there has been a worrying increase in colon cancer rates among younger... Read more

Pathology

view channel
Image: Fingertip blood sample collection on the Babson Handwarmer (Photo courtesy of Babson Diagnostics)

Unique Hand-Warming Technology Supports High-Quality Fingertip Blood Sample Collection

Warming the hand is an effective way to facilitate blood collection from a fingertip, yet off-the-shelf solutions often do not fulfill laboratory requirements. Now, a unique hand-warming technology has... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.